Longevity Supplements: What the Science Actually Supports in 2026

The longevity supplement space sits at a specific intersection of extraordinary scientific progress and extraordinary marketing bullshit.

On one side: legitimate research into the cellular mechanisms of aging — senescent cells, NAD+ decline, mTOR signaling, telomere maintenance — producing genuine insights with real therapeutic implications. On the other: an industry that extracted the vocabulary from that research and applied it to products that have nothing to do with it.

This page applies the same evidence filter to the longevity category that we apply to everything else: what tier of evidence supports each ingredient, what the best studies actually measured, and what’s being extrapolated beyond the data.

Educational content. Not medical advice.

How to Think About Longevity Research

The central challenge: the gold standard for longevity research is a study that actually measures lifespan. That study takes decades and costs more than any supplement company can fund. So most longevity research — including the best of it — uses proxy endpoints:

Biomarker endpoints: Changes in NAD+, inflammatory markers, telomere length, senescent cell burden
Disease endpoints: Reduction in cancer, cardiovascular disease, cognitive decline
Animal lifespan endpoints: Actual lifespan extension in model organisms (worms, mice)
Human safety and biomarker endpoints: Shorter-term studies showing mechanistic activity in humans

None of these is the same as “this supplement makes humans live longer.” All of them are meaningful signals about mechanisms that likely matter. The honest framing is: “this compound acts on a pathway that the science suggests is relevant to how and why we age.”

With that filter in place, here’s what holds up.

The Core Mechanisms of Aging

Understanding the mechanisms helps you evaluate ingredient claims:

Cellular Senescence

Cells accumulate DNA damage, telomere shortening, and oxidative stress over time. When damage exceeds a threshold, cells can either die (apoptosis) or enter senescence — a zombie-like state where they stop dividing but don’t clear themselves. Senescent cells secrete a cocktail of inflammatory signals called the SASP (Senescence-Associated Secretory Phenotype) that damages surrounding tissue, drives chronic inflammation, and impairs organ function.

Why it matters: Senescent cells accumulate in every major tissue as we age. Clearing them — senolysis — is one of the most promising anti-aging targets in current research. Animal studies removing senescent cells genetically consistently extend healthy lifespan.

NAD+ Decline

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme essential for energy metabolism, DNA repair (via PARP enzymes), and sirtuin activation. NAD+ levels decline ~50% between age 20 and 50. This decline impairs cellular energy production, reduces DNA repair capacity, and decreases sirtuin activity — all pathways associated with accelerated aging.

mTOR Signaling

mTOR (mechanistic target of rapamycin) is a nutrient-sensing pathway that integrates growth signals. High mTOR activity promotes cellular growth and replication. Low mTOR activity (as during caloric restriction or fasting) promotes autophagy — cellular cleanup and recycling. Chronically elevated mTOR is associated with accelerated aging. Rapamycin, an mTOR inhibitor, is the most reproducible lifespan-extending drug across animal models.

Mitochondrial Function

Mitochondria produce ATP and are the primary site of reactive oxygen species (ROS) generation. Mitochondrial dysfunction — damaged mitochondria that produce more ROS and less ATP — is both a cause and consequence of aging. Maintaining mitochondrial function and quality control (mitophagy) is a core anti-aging target.

Chronic Inflammation

Low-grade systemic inflammation (“inflammaging”) correlates strongly with age-related disease burden. It’s driven by senescent cells, gut microbiome shifts, accumulated oxidative damage, and adipose tissue dysfunction. Reducing chronic inflammation — through mechanisms that address root causes rather than just blocking inflammatory signals — is a core longevity strategy.

Tier 1 Longevity Ingredients (Best Evidence)

Senolytics: Quercetin, Fisetin, DHM

Senolytics are compounds that selectively trigger apoptosis in senescent cells without harming healthy cells. This is one of the most exciting and best-supported areas of longevity research.

Quercetin + Dasatinib (Kirkland protocol): The first human senolytic trial (Mayo Clinic, 2019) used quercetin + dasatinib (a cancer drug) in patients with idiopathic pulmonary fibrosis. Results showed reduced senescent cell burden and improvement in physical function. Quercetin specifically has multiple rodent model studies showing lifespan extension when combined with dasatinib.

Fisetin: Administered to aged mice, fisetin (a flavonoid in strawberries) cleared senescent cells and extended both median and maximum lifespan. One of the cleaner rodent longevity results. Human trials are in early stages.

DHM — via PRDX2 (2026): The March 2026 Nature Communications study identified DHM as a novel senolytic through a distinct mechanism — binding PRDX2 (peroxiredoxin-2), a cellular redox sensor. In aged murine models, DHM reduced cardiac fibrosis, neuroinflammation, and improved physical performance markers.

DHM’s senolytic mechanism is different from quercetin/fisetin — different target protein, which suggests complementary rather than redundant activity. DHM is currently the only senolytic with both liver health human clinical data (2026 MASLD RCT) and a published Nature-family mechanistic study.

→ DHM as a Senolytic: 2026 Nature Communications Breakdown →

Practical note on senolytics: Current clinical practice uses pulsed senolytic dosing — higher doses intermittently (2–3 days on, weeks off) rather than constant low-dose use. The rationale: senolytics need to reach cells, trigger clearance, and then allow recovery. The optimal human dosing protocol is still being researched.

NMN and NR (NAD+ Precursors)

Both nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) raise NAD+ levels in humans — this has been confirmed in multiple human trials. NAD+ levels decline with age; raising them is a plausible anti-aging intervention.

What the evidence supports: Increased NAD+ levels (Tier 1 human evidence). Functional improvements in some aging biomarkers (early Tier 1 human evidence, smaller studies).

What it doesn’t yet prove: Lifespan extension in humans. The connection “higher NAD+ → longer life” is mechanistically plausible but hasn’t been demonstrated in a human trial — because that trial would take decades.

Dose: 250–500mg NMN/day (sublingual or enterically absorbed formulations preferred). NR at similar doses.

Rapamycin (Prescription Only — Context for Reference)

Rapamycin is an mTOR inhibitor with the most reproducible lifespan extension data across animal models of any compound currently known. It extends lifespan in every organism tested. Human trials (PEARL study, Dog Aging Project) are ongoing.

Not a supplement — prescription drug with significant side effects at immunosuppressive doses. Intermittent low-dose protocols are being studied for longevity specifically, with better side effect profiles. Mentioned here because it’s the mechanistic gold standard against which supplement ingredients are compared.

Metformin (Prescription — Context)

First-line type 2 diabetes drug with epidemiological data showing lower all-cause mortality in diabetics taking it vs. matched non-diabetic controls. The TAME trial (Targeting Aging with Metformin) is the first formal human lifespan trial. Activates AMPK, indirectly inhibits mTOR.

Again, not a supplement — context for where the mechanistic framework comes from.

Tier 2 Longevity Ingredients (Good Mechanism, Earlier Evidence)

Resveratrol

SIRT1 activator; massive early hype based on yeast/worm studies and David Sinclair’s lab work. Human trials have been mixed to disappointing. Bioavailability is poor with standard oral resveratrol. Pterostilbene (methylated resveratrol analog) has better bioavailability and similar mechanism.

Honest status: Biologically interesting, human evidence for longevity endpoints remains thin. Likely meaningful at higher doses with better formulations than most products deliver.

Spermidine

Polyamine compound that induces autophagy (cellular cleanup). Human observational data shows inverse correlation between dietary spermidine and all-cause mortality. Supplementation trials show improvement in some aging biomarkers. Mechanistically compelling; human trial evidence building.

Dose: 1–5mg/day from supplements or dietary sources (wheat germ, mushrooms, aged cheese).

Urolithin A

Metabolite of ellagic acid (pomegranates) produced by gut bacteria. Activates mitophagy — selective clearance of damaged mitochondria. Human trial data (Amazentis/Mitopure): improved mitochondrial function biomarkers and muscle performance in aging adults. Tier 1 human evidence emerging.

One of the better-validated longevity supplements with actual human clinical data.

Dose: 500–1,000mg/day (as used in clinical studies).

What Doesn’t Hold Up

Generic antioxidants (vitamin E, beta-carotene): The antioxidant theory of aging has been substantially revised. High-dose antioxidant supplementation has actually increased mortality in some trials (SELECT trial for vitamin E, ATBC trial for beta-carotene). The free radical theory predicted that flooding the body with antioxidants would slow aging. The data doesn’t support it. Mitochondria need some ROS for signaling; indiscriminate quenching can disrupt that.

Collagen peptides for longevity: Relevant for skin appearance. Not relevant for cellular aging mechanisms. Different category.

Most “anti-aging” branded products: If the ingredient list doesn’t include senolytics, NAD+ precursors, or compounds with documented effects on aging pathways, it’s branding rather than mechanism.

The Longevity Stack (Evidence-Based)

Ingredient	Primary Mechanism	Evidence Level	Dose
DHM	Senolytic (PRDX2), anti-inflammatory	Tier 1 human (liver) + Tier 3 senolytic	300–1,000mg/day
Quercetin	Senolytic (Bcl-2 family)	Tier 1 human (with dasatinib)	500–1,000mg (pulsed)
Fisetin	Senolytic	Tier 3 animal	100–500mg (pulsed)
NMN or NR	NAD+ restoration	Tier 1 human (NAD+ levels)	250–500mg/day
Urolithin A	Mitophagy	Tier 1 human (emerging)	500–1,000mg/day
Spermidine	Autophagy	Tier 2 human observational	1–5mg/day

Note on senolytics: Pulsed dosing (2–3 days on, 2–4 weeks off) is current clinical practice pending better human data on optimal frequency.

DHM’s Place in the Longevity Stack

Hovenia positions DHM at the intersection of three evidence streams: acute alcohol metabolism support, liver health (human clinical trial), and longevity (senolytic mechanism, 2026).

This is why DHM makes sense as a daily supplement even for people who aren’t focused on hangover recovery. The senolytic mechanism is relevant to anyone. The liver health benefits are relevant to anyone. And if you also drink socially, the alcohol metabolism mechanisms make it the best-supported acute recovery ingredient in the category.

→ What Is DHM? Complete Guide → → DHM Senolytic Study: 2026 Nature Communications → → Natural Senolytic Supplements →